It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LLY’s FA Score shows that 2 FA rating(s) are green while.
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LLY’s TA Score shows that 4 TA indicator(s) are bullish.
LLY (@Pharmaceuticals: Major) experienced а -10.11% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -4.55%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was +2.00%.
LLY is expected to report earnings on Jan 30, 2025.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
LLY | ||
---|---|---|
OUTLOOK RATING 1..100 | 57 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 6 | |
SMR RATING 1..100 | 17 | |
PRICE GROWTH RATING 1..100 | 62 | |
P/E GROWTH RATING 1..100 | 86 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LLY | SIXA | |
---|---|---|
RSI ODDS (%) | 3 days ago72% | 4 days ago55% |
Stochastic ODDS (%) | 3 days ago73% | 3 days ago56% |
Momentum ODDS (%) | 3 days ago48% | 3 days ago90% |
MACD ODDS (%) | 3 days ago47% | 3 days ago82% |
TrendWeek ODDS (%) | 3 days ago54% | 3 days ago64% |
TrendMonth ODDS (%) | 3 days ago51% | 3 days ago65% |
Advances ODDS (%) | 7 days ago71% | 7 days ago85% |
Declines ODDS (%) | 3 days ago52% | 3 days ago65% |
BollingerBands ODDS (%) | 3 days ago67% | 3 days ago86% |
Aroon ODDS (%) | 3 days ago57% | 3 days ago84% |
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with NVS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then NVS could also see price increases.
A.I.dvisor tells us that SIXA and ORCL have been poorly correlated (+15% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SIXA and ORCL's prices will move in lockstep.
Ticker / NAME | Correlation To SIXA | 1D Price Change % | ||
---|---|---|---|---|
SIXA | 100% | -0.94% | ||
ORCL - SIXA | 15% Poorly correlated | -1.77% | ||
LLY - SIXA | 14% Poorly correlated | -4.93% | ||
CRM - SIXA | 13% Poorly correlated | -1.93% | ||
AAPL - SIXA | 11% Poorly correlated | -1.41% | ||
COST - SIXA | 10% Poorly correlated | -1.82% | ||
More |